-
Ranjana Advani, MD; Stanford University #BtC_ASCO21
15:14
Dr. Ranjana Advani shares strategies for Integrating Recently Approved Therapies for B-cell NHL Into Practice.
-
Gail Roboz, MD; Weill Cornell Medicine #BtC_ASCO21
12:35
Dr. Gail Roboz presents on Personalizing Therapy for Adult Patients with ALL.
-
Selina Luger, MD, FRCPC; University of Pennsylvania #BtC_ASCO21
18:13
Dr. Selina Luger discusses Biomarkers and their Implications for Therapy in AML.
-
Alison J. Moskowitz, MD; Memorial Sloan Kettering Cancer Center #BtC_ASCO21
16:28
Dr. Alison Moskowitz presents on Treatments for Upfront and Relapsed Hodgkin’s Lymphoma.
-
Jennifer R. Brown, MD, PhD; Dana-Farber Cancer Institute #BtC_ASCO21
15:33
Dr. Jennifer Brown reviews Recently Presented Data of Clinical Trials and Standard of Care in Relapsed/Refractory CLL.
-
Maria-Victoria Mateos, MD, PhD; University of Salamanca #BtC_ASCO21
13:10
Dr. Maria-Victoria Mateos discusses Recently Presented Data of Clinical Trials and Standard of Care in Relapsed/Refractory MM
-
John P. Leonard, MD; Weill Cornell Medicine #BtC_ASCO21
16:48
Dr. John Leonard discusses Recently Presented Data of Clinical Trials in Patients with NHL.
-
Nicole Lamanna, MD; Columbia University #BtC_ASCO21
16:56
Dr. Nicole Lamanna discusses Practical Issues in Treating CLL: Sequencing, Oral Adherence, Managing Adverse Events, and MRD Analysis.
-
Sagar Lonial, MD, FACP; Emory University #BtC_ASCO21
14:48
Dr. Sagar Lonial reviews Recently Presented Data of Clinical Trials and Standard of Care in Upfront Treatment for MM
-
Naveen Pemmaraju, MD; MD Anderson Cancer Center #BtC_ASCO21
14:58
Dr. Naveen Pemmaraju discusses Using and Sequencing JAK Inhibitors for Patients with Myelofibrosis.
-
Matthew Davids, MD, MMSc; Dana-Farber Cancer Inst. #BtC_ASCO21
15:27
Dr. Matthew Davids reviews Recently Presented Data of Clinical Trials and Standard of Care in Upfront Treatment for CLL.
- Next Page
ABOUT
Bio Ascend is an independent medical education company committed to supporting healthcare providers in their efforts to translate innovative science into clinical practice.
The Bio Ascend team has deep oncology and hematology expertise with a proven ability to distill complex scientific ideas into their essential components, as well as extensive experience in planning, executing, and assessing meaningful education for clinicians.
CONNECT
© Copyright 2021 Bio Ascend, a Vaniam Group company